Palette Life Sciences Announces European Distribution Expansion for Deflux® and Solesta® for More Than 20 Countries Through Five Leading Distributors and Direct Sales
Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced global distribution expansion for two of Palette's products, Deflux and Solesta. The expansion provides commercial access to more than 20 countries through five distributors around the globe, while adding direct sales in four additional countries: Cyprus, Greece, Hungary and Portugal.
SANTA BARBARA, Calif. and STOCKHOLM, June 15, 2020 /PRNewswire-PRWeb/ -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced global distribution expansion for two of Palette's products, Deflux and Solesta. The expansion provides commercial access to more than 20 countries through five distributors around the globe, while adding direct sales in four additional countries: Cyprus, Greece, Hungary and Portugal.
KEBOMED, a leading European distributor of medical devices and equipment, will distribute the products in France, Sweden, Norway, Finland, Denmark and Iceland. Stratarium Sarl, will commercialize the products in Germany, Austria, Belgium, Germany, Luxembourg, Netherlands and Switzerland leveraging their urology focused subsidiary, RA Distribution. CJ Medical, a UK-based distributor of innovative technologies specializing in surgical and medical devices, will distribute the products in Ireland and the United Kingdom. Grifols, one of the leading companies in the production and sale of plasma-derived medicines and a top distributor of a broad range of products within their country will cover Spain, and GP Dermal, a specialist with deep ties across urology and pediatric call points will serve as the distributor in Italy and Malta.
"This enhanced distribution network allows Palette to ensure our customer and patient needs are adequately met across Europe," said James Leech, Head of Corporate Development, Palette Life Sciences. "We have selected strong partners with deep experience and relationships in the urology and pediatric setting who will help us serve the product and education needs of physicians and hospitals. Palette and its network of partners are making significant investments within local markets to improve physician access to Palette resources, best management and treatment practices, and renewed product training."
For more information or to place an order, please contact a Palette Life Sciences representative at [email protected]. Contact information for product orders or inquires by distributor are as follows:
KEBOMED: [email protected]
Stratarium Sarl: [email protected]
CJ Medical: [email protected]
Grifols: [email protected]
GP Dermal: [email protected]
About Deflux
Deflux is a minimally invasive, outpatient treatment that has been proven safe and effective in children with vesicoureteral reflux (VUR). VUR is a serious pediatric urinary condition in which urine refluxes from the bladder through one or both ureters toward the kidneys, due to an abnormality at the junction of the ureter and the bladder. Deflux is an injectable gel bulking agent made from two tissue-friendly polysaccharides; Non-Animal Stabilized Hyaluronic Acid (NASHA®) and dextranomer (Dx) microspheres. The product is administered via injection around the ureteral opening to prevent urine reflux. Deflux is indicated in the United States for children with VUR grades II-IV, and is indicated outside of the United States for all grades of VUR. It is the recommended first-line treatment for VUR.1 Separate study results show Deflux is an efficacious long-term (15 – 25 years) treatment option for VUR grade IV2 with up to 93% success rates after a one time injection and no post-injection febrile UTIs (19 month results).3 Deflux is the only minimally invasive VUR treatment approved globally across Australia, Canada, Europe, Latin America, Japan, New Zealand and the United States. For more information, visit http://www.deflux.com
About Solesta
Solesta is a minimally invasive, outpatient treatment for bowel incontinence. Bowel (or fecal) incontinence affects millions of individuals of all ages worldwide. Solesta is an injectable gel made from two polysaccharides; Non-Animal Stabilized Hyaluronic Acid (NASHA®) and dextranomer (Dx) microspheres. The Solesta implant is administered via injection in an outpatient setting without the need for anesthesia.4 Healthcare providers and patients can be confident in the demonstrated durability, safety, and efficacy of Solesta through 36 months. The product has been proven to reduce the number of fecal incontinence episodes, with greater than 80% of patients not requiring retreatment, and enable clinically and statistically significant improvements in quality of life through this time period.5 For more information, visit http://www.mysolesta.com
About Palette Life Sciences AB
Palette Life Sciences is a fully integrated life sciences company. Palette's products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company's portfolio of available products includes Deflux®, Solesta® and Barrigel®. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden with offices in Santa Barbara, California and Dallas, Texas. Learn more at http://www.palettelifesciences.com.
References:
1. Elder JS, Shah MB, Batiste LR, Eaddy M. Part 3: Endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infection in patients with vesicoureteral reflux. Curr Med Res Opin. 2007;23(4):S15-20.
2. Stenbäck A, Olafsdottir T, Sköldenberg E, Barker G, Läckgren G. Non-animal hyaluronic acid/dextranomer gel (Deflux®) endoscopic treatment in grade IV VUR results after 15-25 years: durable and effective. J Pediatr Urol. 2020.
3. Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesicoureteral reflux. J Pediatr Urol. 2012;9(4)359-365.
4. Solesta [Package Insert]. Santa Barbara, CA: Palette Life Sciences.
5. Solesta Post Approval Study Clinical Study Report. December 2019.
Deflux®, NASHA®, Solesta® Palette Life Sciences™ and are registered trademarks. All rights reserved. APM210A
SOURCE Palette Life Sciences
Share this article